Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial.

Authors

Pablo Serrano Aybar

Pablo Emilio Serrano Aybar

McMaster University, Hamilton, ON, Canada

Pablo Emilio Serrano Aybar , Chu-Shu Gu , Mohamed Husien , Diederick Jalink , Guillaume Martel , Melanie E. Tsang , Julie I. Hallet , Steven Gallinger , Anne Ritter , Vivian McAlister , Nathalie Sela , Hannah Solomon , Kaitlyn Beyfuss , Christine Li , Erika Lee , Carolanne Moulton , Mark Norman Levine

Organizations

McMaster University, Hamilton, ON, Canada, Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada, Grand River Regional Cancer Centre, Kitchener, ON, Canada, Hotel Dieu Hospital, Kingston, ON, Canada, Ottawa Hospital, Ottawa, ON, Canada, University of Toronto, Toronto, ON, Canada, Odette Cancer Centre, Toronto, ON, Canada, Mount Sinai Hospital, Toronto, ON, Canada, Queen's University, Kingston, ON, Canada, Western University, London, ON, Canada, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, Toronto General Hospital, University Health Network, Toronto, ON, Canada

Research Funding

Other

Background: The PETCAM randomized trial evaluated the effect of preoperative PET-CT (vs. no PET-CT) on surgical management in patients with colorectal cancer liver metastases. In this study, 8% of patients had a change in surgical management, including a higher proportion of major liver resections in the PET-CT arm. The current study compares the intervention groups for 5-year disease free (DFS) and overall survival (OS), and evaluated their long-term clinical course, i.e. sites of recurrence and management of disease recurrence. Methods: Recruitment to the trial occurred between 2005-2010, with last follow-up in 2013. Data on recurrence, management of recurrence and mortality from 2013-2017 was collected from patient’s charts. Recurrences according to site and management were described. Cox proportional Hazard Models were used to calculate the risk for recurrence and death. OS was calculated with Kaplan-Meir method and compared with log-rank test. Results: At 5 years, 157 of 404 (39%) patients were still alive and 19 patients were lost to follow-up. Median follow-up is 4.2 years. There were no differences in DFS (HR: 1.12, 95%CI: 0.88-1.42) or OS (HR: 0.97, 95%CI: 0.74-1.28) between groups. The median DFS for the 372 patients who had surgery was 17 months, 95%CI: 14.7-19.4. Risks factors for recurrence were: extrahepatic disease, liver tumour size, and nodal stage. The median OS for all patients was 50 months, 95%CI: 43.5-64.3. Risks factors for death also included age and prior use of chemotherapy. During the follow-up period, 287/404, 71% patients recurred (mostly liver and lung); 137 (48%) were treated solely with chemotherapy and 35% were treated with surgery with curative intent. Of these, the majority recurred (109/116, 94%). The median OS following first recurrence was 27.5 months, 95%CI: 23-30. Conclusions: PET-CT did not improve DFS or OS. Survival following liver resection is similar to previous reports, however most patients experience disease recurrence. A substantial proportion of patients who recur undergo surgery, however it is likely that they will recur again.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Prevention, Diagnosis, and Screening

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 562)

DOI

10.1200/JCO.2018.36.4_suppl.562

Abstract #

562

Poster Bd #

A11

Abstract Disclosures